{"term":"Keytruda pembrolizumab bladder cancer","category":"conventional","results":[{"title":"Padcev and Keytruda Double Bladder Cancer Survival - NCI","url":"https://www.cancer.gov/news-events/cancer-currents-blog/2023/bladder-cancer-padcev-keytruda-doubles-survival","description":"For the first time in decades, ... trials. One treatment—the combination of enfortumab vedotin (Padcev) and the immunotherapy drug pembrolizumab (Keytruda)—proved to be particularly powerful....","siteName":"www.cancer.gov"},{"title":"Non-Muscle Invasive Bladder Cancer (NMIBC) - KEYTRUDA® (pembrolizumab) - Patients","url":"https://www.keytruda.com/non-muscle-invasive-bladder-cancer/","description":"It may be used alone when your bladder or urinary tract cancer has spread or cannot be removed by surgery (locally advanced or metastatic urothelial cancer), and you have received chemotherapy that contains platinum, and it did not work or is no longer working.","siteName":"www.keytruda.com"},{"title":"KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery - Merck.com","url":"https://www.merck.com/news/keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-significantly-improved-event-free-and-overall-survival-and-pathologic-complete-response-rate-for-certain-patients-with-muscle/","description":"In this study, KEYTRUDA® (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv), given before and after surgery (radical cystectomy), demonstrated a statistically significant and clinically meaningful improvement in event-free survival (EFS), the ...","published":"August 12, 2025","siteName":"www.merck.com"},{"title":"Advanced Urothelial Bladder Cancer | KEYTRUDA® (pembrolizumab) | Patients","url":"https://www.keytruda.com/advanced-urothelial-bladder-cancer/","description":"It may be used alone when your bladder or urinary tract cancer has spread or cannot be removed by surgery (locally advanced or metastatic urothelial cancer), and you have received chemotherapy that contains platinum, and it did not work or is no longer working.","siteName":"www.keytruda.com"},{"title":"FDA Approves Updated Indication for Merck's KEYTRUDA® (pembrolizumab) for Treatment of Certain Patients With Urothelial Carcinoma (Bladder Cancer) - Merck.com","url":"https://www.merck.com/news/fda-approves-updated-indication-for-mercks-keytruda-pembrolizumab-for-treatment-of-certain-patients-with-urothelial-carcinoma-bladder-cancer/","description":"KEYTRUDA Approved for Treatment of Patients With Locally Advanced or Metastatic Urothelial Carcinoma Who Are Not Eligible for Any Platinum-Containing Chemotherapy Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced ...","published":"March 8, 2025","siteName":"www.merck.com"}]}
